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BRIEF REPORT
Tropomyosin autoantibodies associated with checkpoint inhibitor myositis
Pauline Zaenkera*, David Prenticeb*, and Melanie Zimana,c
aSchool of Medical and Health Sciences, Edith Cowan University, Perth, Australia; bGeneral Medicine Department, St John of God Midland Public 
Hospital, Midland, Australia; cDepartment of Biomedical Science, The University of Western Australia, Perth, Australia
ABSTRACT
This brief report details the measurement and identification of IgA antibodies to tropomyosin in a case of 
presumed ocular myositis with paraspinal myositis in a patient with metastatic uveal melanoma treated 
with checkpoint inhibitors. High-throughput functional protein microarray analysis and pathway analysis 
was conducted to identify IgG and IgA antibodies of interest. Antibody levels were compared to generic 
antibody screening results and levels of the antibodies in a cohort of melanoma patients without myositis 
(n = 100) at baseline prior to undergoing immunotherapy. The finding of specific muscle antibodies in this 
clinical case indicates the pathogenic potential of anti-tropomyosin IgA in the development of checkpoint 
inhibitor associated myositis and requires further investigation.
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We recently reported a case of presumed ocular myositis with 
paraspinal myositis in a patient with metastatic uveal mela-
noma treated with checkpoint inhibitors Pembrolizumab and 
Ipilimumab/Nivolumab.1 Conventional IgG autoantibody 
screening in this case was negative (anti-AChR, anti- 
ganglioside, myositis specific antibodies and anti-MuSK). The 
patient’s level of creatine kinase (2452 U/l) and troponin I (0.36 
micrograms/l) was elevated and an MRI of the cervical muscle 
was consistent with myositis.
Serum was taken, two days after hospital admission and prior 
to steroid and intravenous immunoglobulin infusion that 
achieved complete clinical response. Unfortunately, the patient 
passed away at 12 months post immunotherapy commencement 
due to cerebral metastases and a further trial of radiotherapy and 
other checkpoint inhibitors. Retrospective informed consent was 
obtained from the legal representative of the deceased and is 
available upon request. The serum was analyzed by microarray 
for IgG and IgA binding efficiencies (Supplementary Tables 1 
and 2, respectively) to greater than 21000 antigens (>81% of the 
human proteome) using the HuProtTM microarray (CDI 
Laboratories, USA). The sample was probed on the array at 
a 1:1000 dilution and analyzed for Z scores, which identified 84 
and 172 positive hits (Z score > 3) for IgG and IgA respectively. 
Log2 fold changes (log2FC) were calculated by dividing the case 
signal intensity for each antigen by the mean case signal intensity 
of all antigens or the median signal intensity of all antigens 
across the cohort of other metastatic melanoma samples. In 
particular, the microarray results demonstrated high levels of 
IgA antibodies to tropomyosin (TPM) isoforms 1, 2 and 3 while 
IgG antibodies to these antigens were found to be negative. 
Tropomyosin 3 is essential for melanoma metastasis, enabling 
pseudopodium and invadopodium formation.2 Sera from 
a group of metastatic melanoma patients without myositis 
(n = 100) at baseline prior to undergoing immunotherapy who 
were also screened on the array (unpublished, Edith Cowan 
University Ethics Committee application number 18957) were 
negative to these antigens (Figure 1).
The log2 IgA and IgG data for all antigens in this case 
study was then uploaded to Advaita Bio’s iPathwayGuide 
(http://www.advaitabio.com/ipathwayguide) software to 
determine major pathways enriched by the differentially 
elevated antibodies (p-value < 0.05 and a |log2FC| > 3.47 
(Z score > 3). A detailed description of the pathway analy-
sis approach utilized is described elsewhere.3 Using this 
software, a total of 97 elevated antibodies were identified 
and 19 biological pathways were found to be significantly 
impacted, with cardiac muscle contraction, carbon metabo-
lism and hypertrophic cardiomyopathy pathways showing 
the most significant involvement in the case study’s IgA 
binding profile (p = 5.188 x 10−4, p = .004, p = .007, 
respectively). Similar to the microarray results, the most 
significant identified biological components associated 
with the case IgA binding profile, included muscle thin 
filament tropomyosin, striated muscle thin filament and 
myofilament (p = 7.4 x 10−7, p = 8.1 x 10−5, p = 9.9 
x 10−5, respectively).
Myositis is an autoimmune/antibody-mediated condition 
and several myositis-related and -associated autoantibodies 
have been identified to date.4,5 The regionalization of the 
myositis (paraspinal, ocular and myocardial) in this case is 
interesting as in a mouse model of muscular dystrophy, dele-
tion of a tropomyosin 3 isoform (Tpm3.1) caused muscle 
disease in a similar distribution.6 Garaud et al.7 performed 
microarray antibody analysis in breast cancer, with sera and 
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breast tissue displaying high levels of tumor specific IgA to 
tumor antigens, including cancer/testis antigen 1B (CTAG1B) 
and ankyrin repeat domain 30B like protein (ANKRD30BL). 
These were not related to tumor progression or survival. There 
was however, a correlation with the development of tertiary 
lymphoid structures within the tumor suggesting local IgA 
production. B cell infiltration in tumors is rare but B cell 
activation does occur in primary, secondary and tertiary lym-
phoid structures and antibodies may play a role in tumor 
destruction or progression. Whilst IgA is unable to directly 
activate the complement pathway, it can do so via the mannose 
lectin pathway. It is now recognized that monomeric IgA 
opsonised on cell membranes is able to cause apoptosis and 
necrosis by binding to the FcαR1 receptor (CD89) on 
neutrophils.8 The exact mechanism of subsequent tissue 
damage is under debate and a new novel process called tro-
goptosis has been suggested.9
In summary, the finding of specific muscle antibodies in this 
case may have played a role in the checkpoint induced myositis 
and further studies are required to elucidate the pathogenic 
potential of anti-tropomyosin IgA antibodies.
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Figure 1. Comparison of IgA and IgG levels to tropomyosin isoforms 1, 2 and 3 in 
the reported clinical case study. IgA levels from the sera of a group of metastatic 
melanoma patients without myositis (n = 100) at baseline prior to undergoing 
immunotherapy are also illustrated. Levels are presented as Log2 fold changes 
(log2FC) and were calculated by dividing the case signal intensity for each antigen 
by the mean case signal intensity of all antigens or the median signal intensity of 
all antigens across the cohort of other metastatic melanoma samples. The 
horizontal line at log2FC = 3.47 represents the cutoff where the case Z score > 
3, indicating a positive signal intensity.
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